CDCA8 (Cell Division Cycle Associated 8)

Furthermore, the identified biomarker CDCA8 represents a promising therapeutic target warranting further investigation. These discoveries provide novel evidence on senescence in HCC, which may tailor the pharmacological interventions to improve the clinical management.

Moreover, inhibition of INCENP and CDCA8 enhances NACT sensitivity by promoting multipolar spindle formation. Collectively, our findings establish that INCENP and CDCA8 serve as crucial biomarkers for predicting NACT responsiveness and as potential therapeutic targets for combination therapy with NACT to improve patient survival.

The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.

Collectively, our findings identified HAUS1 as a clinically relevant oncogenic driver that promoted CRC progression and cancer stemness by transcriptionally activating CDCA8. Targeting the HAUS1-EZH2-E2F1-CDCA8 signaling axis might represent a promising therapeutic strategy for CRC.

This study demonstrates that atrazine promotes carcinogenesis by dysregulating conserved networks governing genomic stability, cell proliferation, metabolic adaptation, and immune microenvironment remodeling, providing a mechanistic framework linking aquatic atrazine exposure to multi-organ carcinogenesis and nominating HSD17B8-associated pathways for therapeutic intervention. These findings underscore the imperative for enhanced environmental monitoring of atrazine contamination.

Western blot and qRT-PCR tests validated these genes in GIST-T1 cells, and ssGSEA analysis indicated a significant relationship between these hub genes and immune cell infiltration. This study revealed a set of novel signature genes with high diagnostic value, offering promising targets for the diagnosis and treatment of GIST.

An eight-gene CSC signature captures a stemness-linked G2/M program that generalizes across cohorts, relates to the microenvironment, and is therapeutically tractable via kinase targeting, providing a compact readout for risk stratification and preclinical screening.

Our findings reveal that SUMOylation subtypes in breast cancer exhibit distinct prognostic, immunological and pharmacogenomic profiles. These insights may provide candidate biomarkers for future personalized treatment strategies for breast cancer and potentially for other malignancies.

Glioblastoma (GBM) is a highly aggressive and therapeutically challenging brain tumor characterized by poor prognosis, rapid recurrence, and resistance to standard treatments such as temozolomide (TMZ)...Disruption of CPC function led to reduced mitotic activity and increased mitotic defects in treated cultures. Collectively, these findings indicate that dual inhibition of CDC25 and HDAC by MPT1B394 disrupts CPC-mediated mitosis and aberrant cell cycle progression, representing a promising therapeutic avenue for GBM treatment.

In summary, this study established a prognostic risk model for HCC based on GSH metabolism-related genes, which could predict the prognosis and characterize immune infiltration status of HCC. This study may contribute to the identification of potential prognostic targets and the development of new clinical management strategies for HCC.

HROB is upregulated in LUAD and represents a promising prognostic biomarker, driving tumor proliferation, migration, and invasion.

Lung adenocarcinoma patients have poorer prognosis due to higher levels of CPCs, TMPO-AS1, and E2F1. A sponge complex between TMPO-AS1 and hsa-let-7b-5p may contribute to the tumor progression, and targeting CPCs with natural compounds could offer therapeutic potential. Highlights 1. The overexpression of chromosomal passenger complex genes, AURKB, BIRC5, CDCA8, and INCENP is significantly associated with poor prognosis in lung adenocarcinoma (LUAD), particularly among smokers. 2. The competing endogenous RNA (ceRNA) axis, which involves the long non-coding RNA TMPO-AS1 and the miRNA hsa-let-7b-5p, regulates the expression of these CPC genes. TMPO-AS1 shows a positive correlation with CPC genes, while hsa-let-7b-5p shows a negative correlation. 3. Survival analysis indicates that the combined expression of CPC genes, TMPO-AS1, hsa-let-7b-5p, and E2F1 may serve as a reliable prognostic biomarker panel for LUAD in smokers. 4. Hesperidin exhibits a strong binding affinity to CPC proteins, particularly AURKB, when compared to Barasertib, Docetaxel, and Paclitaxel, highlighting its potential as a therapeutic agent. 5. The overexpression of CPC genes, E2F1, and TMPO-AS1 in LUAD is strongly associated with reduced infiltration of CD4⁺ T cells, indicating their role in promoting an immunosuppressive tumor microenvironment.